Study guide

9.4 Pulmonary Hypertension and Right Ventricular Failure

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

9.4 Pulmonary Hypertension and Right Ventricular Failure

Key Takeaways Explain This Topic AI

Pulmonary hypertension is a mean pulmonary artery pressure above 20 mmHg; pre-capillary requires PAOP 15 mmHg or less with PVR above 2 Wood units, isolated post-capillary is PAOP above 15 with PVR 2 or less, and combined pre- and post-capillary PH is PAOP above 15 with PVR above 2.

PVR in Wood units equals (mean PAP minus PAOP) divided by cardiac output; a diastolic pulmonary gradient of 7 mmHg or more suggests true pulmonary vascular remodeling and is less flow-dependent than the transpulmonary gradient.

Group 2 PH from left heart disease is the most common form in a cardiac unit and is not treated with PAH-targeted vasodilators, which can precipitate flash pulmonary edema.

In acute RV failure the treatment order is inverted from LV failure: restore systemic pressure first with norepinephrine or vasopressin to preserve RV coronary perfusion, then unload the pulmonary circulation selectively with inhaled nitric oxide 5-40 ppm or inhaled epoprostenol; phenylephrine raises PVR and is avoided.

Continuous IV epoprostenol has a 3-6 minute half-life, so an abrupt interruption can cause rebound pulmonary hypertension and death within minutes - the line is dedicated, never flushed, never used for draws, and restarted immediately on the backup pump if it fails.

Last updated: August 2026

Defining Pulmonary Hypertension by the Numbers

Test-plan item II.A.4 is one of the most numerically precise items on the CMC blueprint, and it doubles as a pulmonary artery catheter interpretation question — which is why it earns weight in both Domain II and Domain IV.

Pulmonary hypertension (PH) is a mean pulmonary artery pressure (mPAP) above 20 mmHg at rest, measured by right heart catheterization. The threshold moved down from 25 mmHg with the 2022 ESC/ERS guideline and is now standard in US practice as well. An elevated estimated pulmonary artery systolic pressure on echocardiography raises suspicion; it does not establish the diagnosis, because echo systematically over- and under-estimates depending on the tricuspid regurgitant jet quality.

Pre-capillary versus Post-capillary — the High-Yield Distinction

Two additional numbers separate the categories: the pulmonary artery occlusion (wedge) pressure (PAOP) and the pulmonary vascular resistance (PVR) .

Hemodynamic category mPAP PAOP PVR Meaning

Pre-capillary PH Above 20 mmHg 15 mmHg or less Above 2 Wood units Disease of the pulmonary arterioles or the pulmonary vascular bed (WHO Groups 1, 3, 4)

Isolated post-capillary PH (Ipc-PH) Above 20 mmHg Above 15 mmHg 2 Wood units or less Pure back-pressure from the left heart (WHO Group 2)

Combined pre- and post-capillary PH (Cpc-PH) Above 20 mmHg Above 15 mmHg Above 2 Wood units Left heart disease plus superimposed pulmonary vascular remodeling — worse prognosis, and a decisive variable for LVAD and transplant candidacy

Supporting calculations:

PVR (Wood units) = (mPAP - PAOP) / cardiac output in L/min. Multiply by 80 for dyn-s-cm-5; normal is under 2 Wood units, or under about 160 dyn-s-cm-5.

Transpulmonary gradient (TPG) = mPAP - PAOP. A TPG above 12 mmHg suggests a pulmonary vascular component, but it is sensitive to flow and to PAOP.

Diastolic pulmonary gradient (DPG) = diastolic PAP - PAOP. A DPG of 7 mmHg or more suggests true pulmonary vascular remodeling and is less affected by stroke volume and by the timing of the PAOP reading.

Traps to avoid at the bedside. Read the PAOP at end-expiration , at the level of the mean of the a-wave, with the transducer at the phlebostatic axis. Over-wedging, reading a mean across the respiratory cycle, high PEEP in a West zone 1 or 2 catheter position, or a large v-wave from mitral regurgitation will all falsify the wedge and can manufacture a false Cpc-PH picture — or hide a true one. When the wedge tracing looks wrong, correlate with the PA diastolic pressure, which normally sits within about 4 mmHg of the PAOP in the absence of pulmonary vascular disease. A PA diastolic-to-wedge gradient that widens over time is itself evidence of a developing pulmonary vascular component.

The Five WHO Groups

Group Basis Hemodynamics Cardiac-unit examples Targeted PAH drug therapy?

1 — Pulmonary arterial hypertension (PAH) Pulmonary arteriopathy Pre-capillary Idiopathic, heritable, connective tissue disease (scleroderma), congenital left-to-right shunt and Eisenmenger physiology, drug/toxin (methamphetamine, fenfluramine), HIV, portopulmonary Yes — this is the group the drugs are approved for

2 — PH due to left heart disease Back-pressure Post-capillary, isolated or combined HFrEF, HFpEF, mitral stenosis and regurgitation, aortic stenosis, restrictive cardiomyopathy — by far the most common PH in a cardiac unit No — treat the left heart. PAH drugs can precipitate flash pulmonary edema by increasing flow into a ventricle that cannot accept it

3 — PH due to lung disease and/or hypoxia Hypoxic vasoconstriction, parenchymal loss Pre-capillary COPD, interstitial lung disease, obstructive sleep apnea and obesity hypoventilation, chronic high altitude Generally no; inhaled treprostinil is approved for PH associated with interstitial lung disease

4 — PH due to pulmonary artery obstruction (CTEPH) Chronic organized thromboembolism Pre-capillary The patient still dyspneic 3-6 months after PE — screen with a V/Q scan, not CTPA Pulmonary thromboendarterectomy is potentially curative; riociguat and balloon pulmonary angioplasty for inoperable or persistent disease

5 — Multifactorial or unclear Mixed Variable Sarcoidosis, hemolytic anemia including sickle cell disease, chronic kidney disease and dialysis, metabolic disorders, fibrosing mediastinitis Individualized; treat the underlying disorder